Cytopathology : official journal of the British Society for Clinical Cytology
Ma, C;Ding, F;Li, M;Zhang, L;
PMID: 37177820 | DOI: 10.1111/cyt.13244
Tekin, B;Guo, R;Cheville, JC;Canete-Portillo, S;Sanchez, DF;Fernandez-Nestosa, MJ;Dasari, S;Menon, S;Herrera Hernandez, L;Jimenez, RE;Erickson, LA;Cubilla, AL;Gupta, S;
PMID: 36566905 | DOI: 10.1016/j.humpath.2022.12.012
Penile squamous cell carcinomas (SCC) originating in the shaft are rare. pT1/pT2 categories in the American Joint Committee on Cancer (AJCC) staging manual (8th edition) are poorly defined for SCCs arising in the dorsal shaft as anatomic structures differ between the glans and dorsal shaft (corpus spongiosum vs dartos/Buck's fascia, respectively). We reviewed six penile SCC cases exclusive to the shaft, an unusual presentation, identified amongst 120 patients treated with penectomy. We propose a novel pT staging system for dorsal shaft tumors tailored to its anatomic landmarks, where tumors extending to Buck's fascia are considered pT2 instead of pT1. The mean age at penectomy, average duration of follow-up, and mean depth of invasion were 64 years, 45 months, and 9.8 mm, respectively. Four cases were moderately differentiated, HPV-negative SCCs of the usual type and two cases were HPV-positive basaloid and warty-basaloid carcinomas. Three cases had nodal or distant metastasis at the time of penectomy, and histologic assessment in these cases showed invasion into the Buck's fascia or deeper. According to the current AJCC system, only one of these three cases would be staged as ≥pT2. In contrast, all three metastatic tumors would be staged as ≥pT2 in the proposed model. At last follow-up, one patient died of disease-related complications. Based on this limited series, the proposed staging model appears to suggest better patient stratification for pT1/pT2 stages. This model incorporates Buck's fascia, which has been postulated as a pathway of tumor infiltration. Additional studies are needed to validate this model.
Zhonghua bing li xue za zhi = Chinese journal of pathology
Li, LL;Cui, YY;Gao, PY;Xia, L;Liu, GZ;Liu, H;
PMID: 35785831 | DOI: 10.3760/cma.j.cn112151-20220301-00137
Objective: To investigate the clinicopathological characteristics, immunophenotype, molecular characteristics, differential diagnosis, clinical treatment and prognosis of mixed carcinoma of cervix with adenoid cystic pattern. Methods: Three cases of mixed cervical carcinoma with adenoid cystic pattern were collected at the Affiliated Hospital of Xuzhou University Medical School from 2018 to 2021.The clinicopathological characteristics were analyzed, immunohistochemistry (IHC) and in situ hybridization (ISH) were performed. The related literature was reviewed. Results: The three patients were postmenopausal women with a median age of 74.7 years. The clinical symptom was vaginal bleeding without obvious causes. One case was an endophytic tumor, and the others were exophytic. The median diameter of the three cases was 3.3 cm. Two patients underwent hysterectomy, the tumors infiltrated the external 1/3 and middle 1/3 of the cervix respectively. All the lymph nodes were negative. One patient had a previous biopsy. Microscopically, all three tumors were characterized by a cribriform structure, which were filled with basophilic myxoid substance and surrounded by tubules lined by two layers of cells. The tumor cells had scanty cytoplasm and showed the characteristics of cervical basal-like cells. All three cases were accompanied by high-grade squamous intraepithelial lesions and squamous cell carcinoma, and one also showed a non-specific spindle cell sarcomatoid component. Within the double-layered epithelial structure, the outer epithelium was positive for p63, CD117, p16INK4a (clone E6H4) and MYB protein and negative for S-100 by IHC. The combined positive score of PD-L1 (clone 22C3) was less than 1 in all three cases. Human papillomavirus (HPV) types 16 and 18 were detected in one patient preoperatively, while high-risk HPV were positive in the other two patients by RNAscope ISH postoperatively. None of the three cases showed MYB gene rearrangement by FISH. The mean follow-up time was 23.3 months (36, 28 and 6 months, respectively). Two patients underwent hysterectomy and radiotherapy survived without disease. One patient survived with tumor just by radiotherapy and drug therapy. Conclusions: Mixed cervical carcinoma with adenoid cystic pattern is extremely rare. It is a high-grade malignancy with poor prognosis. The tumor is associated with high-risk HPV infection, without MYB gene rearrangement, and with low PD-L1 immunoreactivity. Radical surgery combined with radiotherapy and chemotherapy is the mainstay of treatment at present.
Histopathology. 2019 Jan 22.
Morgan S, Slodkowska E, Parra-Herran C, Mirkovic J.
PMID: PMID: 30667073 | DOI: DOI:10.1111/his.13825
Abstract AIM: Neuroendocrine carcinoma, small cell type of the uterine cervix (SmCC-Cx) is a rare HPV- related tumor with limited therapeutic options. Merkel cell carcinoma, another virus-associated neuroendocrine malignancy, has significant PD-L1 expression rates. PD-L1 expression has been reported in other malignancies of the cervix. We aimed to determine the prevalence of PD-L1 in the context of mismatch repair protein (MMR) and RB1 expression status in SmCC-Cx. METHODS AND RESULTS: Ten cases of SmCC-Cx were tested for immunohistochemistry expression of PD-L1, MLH1, MSH2, MSH6, PMS2, RB1, CD3, CD20 and HPV in situ hybridization (ISH). PD-L1 expression was scored quantitatively (H-score) in tumor cells and lymphocytes (tumoral/peritumoral). PD-L1 positivity was seen in 7 cases, focal in most cases (H-scores 3 to 140). 3/9 cases showed MMR deficiency. PD-L1 expression levels correlated with MMR expression status: all 3 MLH1/PMS2-deficient cases had a ≥5% PD-L1 staining and an H-score ≥10 (p=0.01). RB1 was lost in 4/9 cases, all PD-L1+, but this correlation was not statistically significant.7/9 tumors were positive for HPV-ISH; two of these had MLH1/PMS2 loss. Among the 2 HPV-ISH negative tumors, one had MLS1/PMS2 loss. CONCLUSIONS: PD-L1 expression, predominantly focal, is seen in 70% of SmCC-Cx, while loss of MMR expression is seen in 33% of SmCC-Cx in our cohort. PD-L1 expression in >10% of tumor cells is seen in a subset of tumors in association with loss of MMR expression. These patients may be amenable to immune checkpoint inhibitor therapy as a promising alternative for this aggressive disease.